TEM,PFE Stock Price and Quote

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -2.72
Percentage change -4.56	%

Peers: ILMN EXAS GH TXG CRSP PACB NTLA EDIT CDNA TWST

| Held by: ARKK VTI VB ARKG VBK ULTY IBB IWP JTEK BAI

Index	-	P/E	-	EPS (ttm)	-4.60	Insider Own	48.04%	Shs Outstand	167.99M	Perf Week	-6.71%
Market Cap	9.85B	Forward P/E	2389.92	EPS next Y	0.02	Insider Trans	-9.16%	Shs Float	89.95M	Perf Month	-18.02%
Enterprise Value	10.49B	PEG	-	EPS next Q	-0.23	Inst Own	33.06%	Short Float	24.51%	Perf Quarter	29.89%
Income	-721.31M	P/S	12.26	EPS this Y	54.57%	Inst Trans	-0.69%	Short Ratio	1.73	Perf Half Y	46.32%
Sales	803.32M	P/B	30.17	EPS next Y	103.32%	ROA	-70.47%	Short Interest	22.04M	Perf YTD	68.48%
Book/sh	1.89	P/C	45.01	EPS next 5Y	-	ROE	-	52W High	91.45 -37.80%	Perf Year	64.87%
Cash/sh	1.26	P/FCF	-	EPS past 3/5Y	-37.97% -32.48%	ROIC	-61.41%	52W Low	31.36 81.38%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.06% 38.58%	Gross Margin	55.42%	Volatility	4.54% 5.88%	Perf 5Y	-
Dividend TTM	-	EV/Sales	13.05	EPS Y/Y TTM	-160.27%	Oper. Margin	-87.17%	ATR (14)	4.00	Perf 10Y	-
Dividend Ex-Date	Jul 18, 2006	Quick Ratio	1.56	Sales Y/Y TTM	42.93%	Profit Margin	-89.79%	RSI (14)	40.34	Recom	2.08
Dividend Gr. 3/5Y	- -	Current Ratio	1.71	EPS Q/Q	27.16%	SMA20	-11.87%	Beta	5.20	Target Price	66.70
Payout	-	Debt/Eq	2.63	Sales Q/Q	75.38%	SMA50	-8.80%	Rel Volume	0.63	Prev Close	59.60
Employees	2400	LT Debt/Eq	2.60	Earnings	May 06 AMC	SMA200	5.85%	Avg Volume	12.71M	Price	56.88
IPO	Jun 14, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.69% 3.07%	Trades		Volume	8,064,181	Change	-4.56%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-21-25	Initiated	BTIG Research	Buy	$60
Feb-25-25	Downgrade	JP Morgan	Overweight → Neutral	$50 → $55
Feb-12-25	Downgrade	William Blair	Outperform → Mkt Perform
Feb-05-25	Resumed	TD Cowen	Buy	$58 → $74
Dec-13-24	Initiated	Wolfe Research	Outperform	$60
Dec-09-24	Initiated	Guggenheim	Buy	$74
Nov-11-24	Downgrade	Stifel	Buy → Hold	$45 → $65
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $60
Aug-12-24	Initiated	Piper Sandler	Neutral	$40
Jul-09-24	Initiated	William Blair	Outperform
Jul-09-24	Initiated	TD Cowen	Buy	$50
Jul-09-24	Initiated	Stifel	Buy	$45
Jul-09-24	Initiated	Needham	Buy	$47
Jul-09-24	Initiated	Morgan Stanley	Overweight	$44
Jul-09-24	Initiated	Loop Capital	Buy	$48
Jul-09-24	Initiated	Longbow	Buy	$48
Jul-09-24	Initiated	JP Morgan	Overweight	$42
Jul-09-24	Initiated	BofA Securities	Buy	$41

Show Previous Ratings

Jul-10-25 12:00PM	Cathie Wood's ARK Loads Up on Tempus AI, Cuts Roku and Block (GuruFocus.com)
04:00AM	The early winner in the 'Dexit' war for corporate relocations: Nevada (Yahoo Finance)
Jul-09-25 08:55PM	Lightning Round: When it comes to AI, I believe in Nvidia, says Jim Cramer (CNBC TV)
04:00PM	Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients (Business Wire)
Jul-08-25 08:30AM	Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer (Business Wire)
09:55AM	Loading…
Jul-07-25 09:55AM	Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches (Zacks)
08:27AM	Here's What Boosted Tempus AI (TEM) in Q1 (Insider Monkey)
08:06AM	TEM Securities Lawsuit Filed Against Tempus AI, Inc. Contact the DJS Law Group to Discuss Your Rights (PR Newswire)
Jul-05-25 12:22PM	Why Tempus AI Stock Soared 15.2% in June (Motley Fool)
Jul-04-25 08:43AM	Tempus AI Revenues & Profit Rise: What to Expect Ahead of Q2 Release (Zacks)
Jul-03-25 12:01PM	Hims & Hers Enhances Healthcare Through AI-Driven Personalization (Zacks)
Jul-02-25 10:28AM	Tempus AI (TEM) Falters on $400-Million Debt Issue (Insider Monkey)
08:11AM	What's Fueling Tempus AI's Explosive Sales Growth? (Zacks)
Jun-30-25 10:43PM	Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes (Business Wire) -6.44%
09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
07:00AM	Loading…
07:00AM	Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense (Business Wire)
02:42AM	Tempus AI's Ambry Genetics Leads with Validated 99.5% Accurate Hereditary Cancer Risk Assessment Tool (Insider Monkey)
Jun-28-25 09:10AM	10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential (Motley Fool)
Jun-27-25 09:15AM	Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last? (Zacks)
Jun-25-25 05:00PM	Ambry Genetics CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing (Business Wire)
10:15AM	Agentic AI Market worth $140.80 billion by 2032- Exclusive Report by MarketsandMarkets (PR Newswire)
Jun-24-25 07:25PM	Tempus AI, Inc. (TEM): A Bull Case Theory (Insider Monkey)
Jun-23-25 03:00PM	TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now? (Zacks)
Jun-20-25 08:41AM	Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building? (Zacks)
Jun-19-25 09:01AM	Biovica International AB (FRA:9II) Q4 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com)
Jun-17-25 09:33AM	Members of Congress Are Pouring Millions Into These 7 Surprising Stocks (Motley Fool)
08:30AM	Tempus to Participate in TD Cowen's 4th Annual Tools/Dx Revolution Conference (Business Wire)
Jun-13-25 12:07PM	Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach (Zacks)
Jun-12-25 03:47PM	Veteran analyst unveils bold price target for Tempus AI stock (TheStreet)
08:30AM	Tempus Announces Collaboration with Northwestern Universitys Abrams Research Center on Neurogenomics to Leverage AI for Alzheimers Disease Research (Business Wire)
03:00PM	Loading…
Jun-09-25 03:00PM	Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today? (Zacks) +7.85%
Jun-06-25 01:55PM	Why Shares of Tempus AI Are Jumping Higher This Week (Motley Fool) +5.81%
09:09AM	Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape? (Zacks)
04:41AM	Zacks Investment Ideas feature highlights: Tempus AI, SoundHound AI and Innodata (Zacks)
Jun-05-25 11:30AM	3 AI Stocks Flying Under the Radar (Zacks) -6.56%
11:07AM	Update! What Is Congress Trading So Far In 2025? (MarketBeat)
05:00AM	Zacks Investment Ideas feature highlights: Nvidia, Alphabet, Constellation Energy and Meta Platform (Zacks)
Jun-04-25 09:45AM	Beyond LLMs: How Propense.ai & Tempus AI are Shaking up Legacy Industries (Zacks)
Jun-03-25 02:23AM	Why Tempus AI, Inc. (TEM) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 05:22PM	Why Tempus AI Stock Soared 15% Today (Motley Fool) +15.02%
04:17PM	Tempus AI recovers 15% as Wall Street downplays Spruce Point allegations (Investing.com)
02:13PM	Tempus AI rebound, Meta's AI ad push, Broadcom earnings optimism (Yahoo Finance Video)
08:30AM	Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers (Business Wire)
Jun-01-25 02:33PM	Cathie Wood buys $13.9 million of popular AI stock (TheStreet)
08:30AM	Introducing Tempus One in the EHR with Integrated Guidelines (Business Wire)
May-31-25 01:33PM	Tempus AI hits back at scathing short report (TheStreet)
08:40AM	Tempus AI announces 10 abstracts accepted for presentation at 2025 ASCO meeting (TipRanks)
08:30AM	Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model (Business Wire)
May-30-25 11:23AM	Tempus AI Stock: Buy the Dip, or Is the Short-Seller Right? (Motley Fool)
10:06AM	Why Tempus AI Stock Plummeted This Week (Motley Fool)
09:09AM	Real-World Deployments Signal AI Healthcare Is Ready for Scale (PR Newswire)
08:30AM	Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting (Business Wire)
May-29-25 05:45AM	Why Tempus AI, Inc. (TEM) Went Down On Wednesday (Insider Monkey)
May-28-25 03:57PM	Tempus AI, Box earnings, Victoria's Secret: Trending Tickers (Yahoo Finance Video) -19.23%
02:32PM	A Cathie Wood Favorite Is Falling: Why Tempus AI Stock Is Imploding Today (Motley Fool)
02:08PM	Nvidia earnings, Tempus AI short, Vail Resorts CEO returns (Yahoo Finance Video)
12:41PM	Why Artificial Intelligence Stock Tempus AI Is Tumbling Today (Motley Fool)
09:10AM	Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Tempus AI, Inc. (Nasdaq: TEM) (Business Wire)
08:30AM	A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years (Business Wire)
May-27-25 06:15AM	New Study Shows Impact of Ambry Genetics Patient for Life Program on Rare Disease Diagnosis (Business Wire) +5.29%
May-26-25 03:00PM	Tempus AI vs. Butterfly: Which AI Health Tech Stock is the Better Buy? (Zacks)
May-23-25 02:30AM	These Investors Search for Extreme Winners. Why Aurora, BYD, Tempus AI Make the Cut. (Barrons.com) +5.59%
May-21-25 12:57PM	Options Trading Now Available on Three Tradr ETFs: QBTX, TEMT and APPX (PR Newswire) -6.87%
08:48AM	Zacks Investment Ideas feature highlights: Palantir, Tempus AI and Comfort Systems USA (Zacks)
08:30AM	Tempus to Present at the William Blair 45th Annual Growth Stock Conference (Business Wire)
May-20-25 11:39AM	Tempus partners with Verastem for companion diagnostic development (Medical Device Network)
11:15AM	These 3 AI-Related Stocks Crushed Earnings (Zacks)
08:30AM	Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment (Business Wire)
07:33AM	From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room (PR Newswire)
May-19-25 11:16AM	Should You be Confident in Tempus AI (TEM)? (Insider Monkey)
May-15-25 03:00PM	After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order? (Zacks)
04:48AM	Boehringer partners Tempus AI to enhance cancer therapy pipeline (Pharmaceutical Technology)
May-14-25 08:30AM	Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline (Business Wire) -5.99%
May-13-25 07:40PM	Why Tempus AI Inc. (TEM) Skyrocketed On Tuesday (Insider Monkey) +9.92%
04:05PM	Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025 (Business Wire)
11:34AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (and Sold) (Motley Fool)
11:11AM	Is Tempus AI, Inc. (TEM) the Best Performing Healthcare Stock to Buy Now? (Insider Monkey)
06:45AM	Tradr Launches First Leveraged ETF on Tempus AI (PR Newswire)
May-10-25 09:50AM	Jim Cramer Says Stay Away from This Nancy Pelosi Stock (Insider Monkey)
07:00AM	MarketBeat Week in Review - 05/05 - 05/09 (MarketBeat)
May-09-25 11:30AM	These AI Stocks Posted Robust Results: Time to Buy? (Zacks) -5.90%
May-08-25 07:45AM	Tempus AI Stock: Time to Double Down or Cut and Run? (MarketBeat) +10.99%
01:48AM	Why Tempus AI, Inc. (TEM) Skyrocketed On Wednesday (Insider Monkey)
May-07-25 12:34PM	Q1 2025 Tempus AI Inc Earnings Call (Thomson Reuters StreetEvents) +12.59%
07:49AM	Tempus AI, Inc. (TEM): Among Most Popular Stocks on Robinhood in 2025 (Insider Monkey)
03:22AM	Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
May-06-25 04:01PM	Tempus Reports First Quarter 2025 Results (Business Wire)
May-05-25 05:07PM	Jim Cramer Warns on Tempus AI (TEM): "Diagnostics With no Dough? I'm Out" (Insider Monkey) -5.24%
12:35PM	AI Healthcare Boom Gains Speed as Regulators and Innovators Align (PR Newswire)
08:30AM	Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry (Business Wire)
May-02-25 08:58AM	Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time. (Motley Fool) +10.05%
05:32AM	Tempus selects TIME Network for Phase I clinical trials (Clinical Trials Arena)
May-01-25 11:04AM	New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty (PR Newswire)
08:30AM	Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment (Business Wire)
Apr-30-25 05:32AM	Is This the Best Nancy Pelosi Stock to Buy After a 40% Pullback? (Motley Fool)
Apr-29-25 08:45AM	Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth (GlobeNewswire)
08:30AM	Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection (Business Wire)
Apr-28-25 03:00PM	Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings? (Zacks)
08:30AM	Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform (Business Wire)
Apr-26-25 02:04PM	Why Tempus AI Inc. (TEM) Soared Last Week (Insider Monkey)

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fukushima Ryan	Chief Operating Officer	Jul 07 '25	Sale	60.00	5,000	300,000	145,000	Jul 09 04:15 PM
VANESSA L KUBO	Officer	Jul 07 '25	Proposed Sale	60.97	20,000	1,219,400		Jul 07 04:16 PM
Doudna Jennifer A	Director	Jul 01 '25	Sale	62.52	625	39,075	26,554	Jul 03 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jun 17 '25	Sale	70.07	250,000	17,516,593	9,357,283	Jun 20 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jun 18 '25	Sale	69.44	250,000	17,359,469	9,307,283	Jun 20 04:15 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Jun 16 '25	Sale	72.56	51,317	3,723,634	97,779	Jun 18 04:15 PM
Polovin Andrew	EVP and General Counsel	Jun 16 '25	Sale	72.13	1,423	102,641	137,454	Jun 18 04:15 PM
Eric Paul Lefkofsky	Officer	Jun 17 '25	Proposed Sale	72.00	400,000	28,800,000		Jun 17 09:45 PM
ERIK PHELPS	Officer	Jun 16 '25	Proposed Sale	71.28	51,317	3,657,876		Jun 16 04:30 PM
ANDREW POLOVIN	Officer	Jun 16 '25	Proposed Sale	71.28	1,423	101,431		Jun 16 04:22 PM
Leonsis Theodore	Director	Jun 11 '25	Sale	67.66	205,847	13,927,976	0	Jun 13 04:15 PM
Revolution Growth Management C	Shareholder	Jun 11 '25	Proposed Sale	69.38	205,847	14,281,665		Jun 11 04:02 PM
Fukushima Ryan	Chief Operating Officer	Jun 03 '25	Sale	62.29	20,000	1,245,764	856,640	Jun 05 04:15 PM
Doudna Jennifer A	Director	Jun 02 '25	Sale	55.20	558	30,802	27,179	Jun 04 04:15 PM
Epstein David R	Director	Jun 02 '25	Sale	55.20	250	13,800	27,661	Jun 04 04:15 PM
JENNIFER A DOUDNA	Director	Jun 02 '25	Proposed Sale	55.18	1,183	65,278		Jun 02 04:32 PM
Rogers James William	Chief Financial Officer	May 20 '25	Sale	63.27	23,121	1,462,809	146,001	May 22 08:00 PM
Polovin Andrew	EVP and General Counsel	May 20 '25	Sale	63.43	17,552	1,113,385	138,877	May 22 08:00 PM
Phelps Erik	EVP & Chief Admin & Legal Off	May 20 '25	Sale	63.21	8,415	531,918	149,096	May 22 08:00 PM
LEFKOFSKY ERIC P	CEO and Chairman	May 20 '25	Sale	63.21	16,752	1,058,905	4,878,837	May 22 08:00 PM
Fukushima Ryan	Chief Operating Officer	May 20 '25	Sale	63.21	7,820	494,308	876,640	May 22 08:00 PM
Bartolucci Ryan M	Chief Accounting Officer	May 20 '25	Sale	63.23	6,073	384,023	47,799	May 22 08:00 PM
Ryan M. Bartolucci	Officer	May 20 '25	Proposed Sale	63.74	4,254	271,150		May 21 07:39 PM
Ryan Fukushima	Officer	May 20 '25	Proposed Sale	63.74	7,820	498,447		May 21 07:36 PM
Andrew Polovin	Officer	May 20 '25	Proposed Sale	63.74	9,797	624,461		May 21 07:25 PM
Eric Paul Lefkofsky	Officer	May 20 '25	Proposed Sale	63.74	16,752	1,067,772		May 21 07:23 PM
Erik Phelps	Officer	May 20 '25	Proposed Sale	63.74	8,415	536,372		May 21 07:20 PM
James William Rogers	Officer	May 20 '25	Proposed Sale	63.74	11,413	727,465		May 21 07:18 PM
RYAN BARTOLUCCI	Officer	May 20 '25	Proposed Sale	63.74	1,819	115,943		May 20 04:32 PM
ANDREW POLOVIN	Officer	May 20 '25	Proposed Sale	63.74	7,755	494,304		May 20 04:31 PM
JAMES ROGERS	Officer	May 20 '25	Proposed Sale	63.74	11,708	746,268		May 20 04:31 PM
Leonsis Theodore	Director	May 09 '25	Sale	66.26	770	51,020	43,550	May 13 04:15 PM
REVOLUTION GROWTH III, LP	Shareholder	May 09 '25	Proposed Sale	65.22	770	50,219		May 09 04:18 PM
Fukushima Ryan	Chief Operating Officer	May 06 '25	Sale	52.36	20,000	1,047,239	884,460	May 08 04:30 PM
Epstein David R	Director	May 01 '25	Sale	53.50	370	19,795	25,914	May 05 04:15 PM
Gottlieb Scott	Director	Apr 01 '25	Sale	47.21	27,837	1,314,154	32,839	Apr 03 05:30 PM
Doudna Jennifer A	Director	Apr 01 '25	Sale	48.12	625	30,075	25,740	Apr 03 04:15 PM
Fukushima Ryan	Chief Operating Officer	Apr 01 '25	Sale	47.20	20,000	944,085	904,460	Apr 03 04:15 PM
Frederick Wayne A.I.	Director	Mar 31 '25	Sale	45.54	3,000	136,620	26,514	Apr 02 06:13 PM
RYAN FUKUSHIMA	Officer	Apr 01 '25	Proposed Sale	48.24	60,000	2,894,400		Apr 01 04:22 PM
Polovin Andrew	EVP and General Counsel	Mar 21 '25	Sale	50.00	3,076	153,800	151,095	Mar 25 04:15 PM
ANDREW POLOVIN	Officer	Mar 21 '25	Proposed Sale	48.04	3,076	147,771		Mar 21 04:21 PM
Rogers James William	Chief Financial Officer	Mar 18 '25	Sale	45.97	23,030	1,058,699	164,750	Mar 19 06:30 PM
Polovin Andrew	EVP and General Counsel	Mar 18 '25	Sale	45.98	13,135	603,970	154,171	Mar 19 06:30 PM
Epstein David R	Director	Mar 17 '25	Sale	46.83	990	46,362	26,284	Mar 19 06:30 PM
West Nadja	Director	Mar 17 '25	Sale	48.86	7,634	372,962	30,071	Mar 19 06:30 PM
Gottlieb Scott	Director	Mar 17 '25	Sale	48.85	27,838	1,359,989	60,676	Mar 19 06:30 PM
Frederick Wayne A.I.	Director	Mar 17 '25	Sale	48.85	9,000	439,659	29,514	Mar 19 06:30 PM
Doudna Jennifer A	Director	Mar 17 '25	Sale	48.80	9,308	454,210	26,365	Mar 19 06:30 PM
ANDREW POLOVIN	Officer	Mar 18 '25	Proposed Sale	49.87	13,135	655,042		Mar 18 04:41 PM
JAMES ROGERS	Officer	Mar 18 '25	Proposed Sale	49.87	23,030	1,148,506		Mar 18 04:27 PM
WAYNE FREDERICK	Director	Mar 17 '25	Proposed Sale	47.17	12,000	566,040		Mar 17 04:47 PM
DAVID R. EPSTEIN	Director	Mar 17 '25	Proposed Sale	47.17	1,610	75,944		Mar 17 04:25 PM
SCOTT GOTTLIEB	Director	Mar 17 '25	Proposed Sale	47.17	55,675	2,626,190		Mar 17 04:23 PM
LEFKOFSKY ERIC P	CEO and Chairman	Mar 05 '25	Sale	50.93	562,345	28,641,725	9,457,283	Mar 07 04:56 PM
LEFKOFSKY ERIC P	CEO and Chairman	Mar 06 '25	Sale	49.83	250,000	12,457,454	9,407,283	Mar 07 04:56 PM
Fukushima Ryan	Chief Operating Officer	Mar 04 '25	Sale	51.15	20,000	1,022,974	924,460	Mar 06 05:05 PM
West Nadja	Director	Mar 04 '25	Sale	51.11	809	41,347	37,705	Mar 06 05:05 PM
Eric P. Lefkofsky	Officer	Mar 05 '25	Proposed Sale	52.73	662,345	34,925,452		Mar 05 05:44 PM
Doudna Jennifer A	Director	Mar 03 '25	Sale	57.52	338	19,442	35,673	Mar 05 04:15 PM
Epstein David R	Director	Mar 03 '25	Sale	57.52	250	14,380	27,274	Mar 05 04:15 PM
NADJA WEST	Director	Mar 04 '25	Proposed Sale	50.93	8,443	430,002		Mar 04 05:08 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 27 '25	Sale	58.75	3,240,234	190,363,748	0	Feb 27 07:39 PM
Lightbank Investments 1B, LLC	Affiliate	Feb 27 '25	Proposed Sale	59.10	115,751	6,840,884		Feb 27 04:27 PM
Innovation Group Investors, L.	Affiliate	Feb 27 '25	Proposed Sale	59.10	1,580,928	93,432,845		Feb 27 04:26 PM
Lightbank Global, LLC	Affiliate	Feb 27 '25	Proposed Sale	59.10	1,397,589	82,597,510		Feb 27 04:25 PM
Innovation Group Investors, L.	Affiliate	Feb 27 '25	Proposed Sale	59.10	145,966	8,626,591		Feb 27 04:24 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 19 '25	Sale	80.87	84,640	6,844,680	4,964,820	Feb 20 07:55 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 20 '25	Sale	74.09	69,231	5,129,325	4,895,589	Feb 20 07:55 PM
Fukushima Ryan	Chief Operating Officer	Feb 19 '25	Sale	81.87	2,868	234,814	944,460	Feb 20 07:55 PM
Bartolucci Ryan M	Chief Accounting Officer	Feb 20 '25	Sale	80.00	1,682	134,560	44,500	Feb 20 07:55 PM
Bartolucci Ryan M	Chief Accounting Officer	Feb 19 '25	Sale	81.87	818	66,973	46,182	Feb 20 07:55 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Feb 18 '25	Sale	82.36	61,582	5,072,077	153,080	Feb 20 07:55 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Feb 19 '25	Sale	81.87	903	73,932	152,177	Feb 20 07:55 PM
Polovin Andrew	EVP and General Counsel	Feb 18 '25	Sale	82.32	64,381	5,299,820	172,857	Feb 20 07:55 PM
Polovin Andrew	EVP and General Counsel	Feb 19 '25	Sale	81.87	5,551	454,470	167,306	Feb 20 07:55 PM
Rogers James William	Chief Financial Officer	Feb 18 '25	Sale	82.33	31,780	2,616,308	189,320	Feb 20 07:55 PM
Rogers James William	Chief Financial Officer	Feb 19 '25	Sale	81.87	1,540	126,086	187,780	Feb 20 07:55 PM
RYAN BARTOLUCCI	Officer	Feb 20 '25	Proposed Sale	85.71	1,682	144,164		Feb 20 04:22 PM
JAMES ROGERS	Officer	Feb 18 '25	Proposed Sale	89.44	31,780	2,842,403		Feb 18 04:29 PM
ANDREW POLOVIN	Officer	Feb 18 '25	Proposed Sale	89.44	64,381	5,758,237		Feb 18 04:29 PM
ERIK PHELPS	Officer	Feb 18 '25	Proposed Sale	89.44	61,582	5,507,894		Feb 18 04:28 PM
Doudna Jennifer A	Director	Feb 14 '25	Sale	90.00	1,320	118,800	36,011	Feb 14 07:53 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 14 '25	Sale	85.78	80,003	6,862,467	5,049,460	Feb 14 04:33 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 13 '25	Sale	78.51	78,594	6,170,792	5,129,463	Feb 14 04:33 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 12 '25	Sale	70.02	84,948	5,948,059	5,208,057	Feb 14 04:33 PM
Bartolucci Ryan M	Chief Accounting Officer	Feb 13 '25	Sale	80.00	6,059	484,720	47,000	Feb 14 04:32 PM
JENNIFER A DOUDNA	Director	Feb 14 '25	Proposed Sale	83.75	11,253	942,439		Feb 14 04:23 PM
RYAN BARTOLUCCI	Officer	Feb 13 '25	Proposed Sale	73.88	6,059	447,639		Feb 13 04:31 PM
LEFKOFSKY ERIC P	Officer	Feb 12 '25	Proposed Sale	71.21	535,000	38,097,350		Feb 12 08:21 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Feb 05 '25	Sale	67.57	5,934	400,960	214,662	Feb 07 05:38 PM
Polovin Andrew	EVP and General Counsel	Feb 05 '25	Sale	67.57	7,717	521,438	237,238	Feb 07 05:36 PM
Rogers James William	Chief Financial Officer	Feb 05 '25	Sale	67.57	8,712	588,670	221,100	Feb 07 05:35 PM
Bartolucci Ryan M	Chief Accounting Officer	Feb 06 '25	Sale	71.00	2,320	164,720	53,059	Feb 07 05:34 PM
Bartolucci Ryan M	Chief Accounting Officer	Feb 05 '25	Sale	67.57	1,858	125,545	55,379	Feb 07 05:34 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 06 '25	Sale	67.89	85,109	5,778,114	5,373,393	Feb 07 05:33 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 07 '25	Sale	67.53	80,388	5,428,398	5,293,005	Feb 07 05:33 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 05 '25	Sale	67.53	74,485	5,030,067	5,458,502	Feb 07 05:33 PM
Fukushima Ryan	Chief Operating Officer	Feb 04 '25	Sale	62.50	20,000	1,250,033	962,442	Feb 06 06:02 PM
Fukushima Ryan	Chief Operating Officer	Feb 05 '25	Sale	67.57	15,114	1,021,253	947,328	Feb 06 06:02 PM

Dollar change -0.13
Percentage change -0.50	%

Peers: BMY MRK SNY AMGN ABBV NVS JNJ GSK LLY AZN

| Held by: VTI VOO SPY IVV VTV XLV VYM COWZ VHT DVY

Index	S&P 500	P/E	18.59	EPS (ttm)	1.38	Insider Own	0.18%	Shs Outstand	5.68B	Perf Week	1.06%
Market Cap	145.83B	Forward P/E	8.31	EPS next Y	3.09	Insider Trans	0.17%	Shs Float	5.67B	Perf Month	5.56%
Enterprise Value	190.92B	PEG	-	EPS next Q	0.57	Inst Own	67.00%	Short Float	1.97%	Perf Quarter	14.05%
Income	7.87B	P/S	2.33	EPS this Y	-3.69%	Inst Trans	0.94%	Short Ratio	2.59	Perf Half Y	-5.46%
Sales	62.46B	P/B	1.61	EPS next Y	3.11%	ROA	3.67%	Short Interest	111.91M	Perf YTD	-3.32%
Book/sh	15.89	P/C	8.42	EPS next 5Y	-0.19%	ROE	8.62%	52W High	31.54 -18.67%	Perf Year	-7.47%
Cash/sh	3.05	P/FCF	13.00	EPS past 3/5Y	-28.65% -13.25%	ROIC	5.32%	52W Low	20.92 22.64%	Perf 3Y	-51.37%
Dividend Est.	1.71 (6.65%)	EV/EBITDA	7.92	Sales past 3/5Y	-7.84% 9.10%	Gross Margin	66.93%	Volatility	1.94% 1.65%	Perf 5Y	-21.57%
Dividend TTM	1.70 (6.63%)	EV/Sales	3.06	EPS Y/Y TTM	2770.58%	Oper. Margin	27.53%	ATR (14)	0.46	Perf 10Y	-18.89%
Dividend Ex-Date	Jul 25, 2025	Quick Ratio	0.96	Sales Y/Y TTM	13.38%	Profit Margin	12.59%	RSI (14)	68.10	Recom	2.44
Dividend Gr. 3/5Y	2.49% 2.97%	Current Ratio	1.26	EPS Q/Q	-5.13%	SMA20	3.74%	Beta	0.49	Target Price	28.21
Payout	119.94%	Debt/Eq	0.69	Sales Q/Q	-7.82%	SMA50	7.39%	Rel Volume	0.73	Prev Close	25.78
Employees	81000	LT Debt/Eq	0.64	Earnings	Aug 05 BMO	SMA200	-0.01%	Avg Volume	43.25M	Price	25.65
IPO	Jan 17, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	38.22% -1.47%	Trades		Volume	34,864,396	Change	-0.50%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$24
Dec-10-24	Resumed	BofA Securities	Neutral	$29
Nov-15-24	Initiated	Wolfe Research	Underperform	$25
Oct-25-24	Resumed	Citigroup	Neutral	$30
Oct-17-24	Initiated	Bernstein	Mkt Perform	$32
Aug-07-24	Upgrade	Daiwa Securities	Neutral → Outperform
Mar-22-24	Downgrade	Argus	Buy → Hold
Feb-23-24	Initiated	Guggenheim	Buy	$36
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$32
Oct-20-23	Resumed	UBS	Neutral	$36 → $34
Oct-16-23	Upgrade	Jefferies	Hold → Buy	$38 → $39
Jul-17-23	Reiterated	JP Morgan	Neutral	$45 → $41
Jul-14-23	Initiated	HSBC Securities	Buy	$50
Jun-29-23	Downgrade	Credit Suisse	Outperform → Neutral	$47 → $40
May-11-23	Downgrade	Daiwa Securities	Outperform → Neutral	$38
Mar-06-23	Initiated	Jefferies	Hold	$43
Feb-07-23	Upgrade	Daiwa Securities	Neutral → Outperform	$51
Jan-26-23	Downgrade	UBS	Buy → Neutral	$55 → $47
Jan-17-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$54 → $50
Jan-04-23	Downgrade	BofA Securities	Buy → Neutral	$60

Show Previous Ratings

Today 05:46AM	Obesity Drug Pipeline Analysis Report 2025 \| Pfizer and Eli Lilly Lead the Charge in Cutting-Edge Obesity Research (GlobeNewswire)
Jul-13-25 05:00PM	China Biotechs Stunning Advance Is Changing the Worlds Drug Pipeline (Bloomberg)
02:48AM	Pfizer (PFE) Reports XTANDI Shows Life-Extending Benefits (Insider Monkey)
Jul-12-25 09:36AM	FDA willing to trade faster drug reviews for lower prices, Bloomberg reports (TipRanks)
Jul-11-25 04:56PM	Big pharma's multiple looming patent cliffs: What to know (Yahoo Finance Video)
12:10PM	Loading…
12:10PM	Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? (Zacks)
10:58AM	MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients (Zacks)
10:05AM	Adrenal Crisis Market Analysis and Forecast Report 2025-2035 with Competitive Benchmarking of Eton Pharmaceuticals, Antares Pharma, and Pfizer (GlobeNewswire)
07:27AM	Pfizer and Astellas Xtandi improves OS as combination therapy (Clinical Trials Arena)
04:21AM	Functional Dyspepsia Market Analysis and Forecast, 2025-2035, Competitive Analysis of AstraZeneca, P&G, Takeda, Prestige Consumer Healthcare, Kenvue Brands, Dr. Reddy's, Pfizer, ZERIA, Daewoong (GlobeNewswire)
04:19AM	Burns Market Analysis and Forecast Report 2025-2035 Featuring Pfizer, Perrigo, Kenvue Brands, 3M, Smith+Nephew, Molnlycke, Cardinal Health, Convatec, Haleon, Coloplast, DeRoyal Industries (GlobeNewswire)
04:07AM	Chlamydia Market Analysis and Forecast, 2025-2035 Featuring ActivBiotics, Bausch Health, Allergan, WCG Clinical, Hologic, Evofem, CRMI, Meridian Bioscience, Pfizer (GlobeNewswire)
04:01AM	Psoriatic Arthritis Market Report 2025-2035 \| Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma (GlobeNewswire)
Jul-10-25 01:30PM	Wednesdays Unusual Options Activity Reveals 3 Standout Long Straddle Plays (Barchart)
09:55AM	Danon Disease Treatment Modality Market Analysis and Forecasts 2025-2035 \| Next-Gen Sequencing Speeds Up Danon Disease Diagnosis and Treatment Pathways (GlobeNewswire)
09:47AM	Loading…
09:47AM	Alcohol Related Liver Disease Market Forecast, 2025-2035 \| Personalized Medicine Transforming ARLD Treatment Landscape (GlobeNewswire)
06:45AM	XTANDI Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence (Business Wire)
Jul-09-25 12:12PM	Pfizer Earnings Preview: What to Expect (Barchart)
09:24AM	Merck Faces Multiple Challenges: Will It Steer Through Successfully? (Zacks)
09:11AM	JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now? (Zacks)
06:35AM	Stocks to Watch Wednesday: Freeport-McMoRan, UnitedHealth, Novo Nordisk (The Wall Street Journal)
01:03AM	Companies Like Pfizer Inc (PFE) are Boosting the Cannabis Light Market (Insider Monkey)
Jul-08-25 05:45PM	Pfizer (PFE) Ascends While Market Falls: Some Facts to Note (Zacks)
04:20PM	Centivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity Portfolio (PR Newswire)
04:01PM	Stock market today: Dow, S&P 500 slip as Trump stays firm on August tariff deadline, announces copper duties (Yahoo Finance)
02:27PM	Stock market today: Dow, S&P 500, Nasdaq steady as Trump says he won't extend Aug. 1 tariff deadline (Yahoo Finance)
02:18PM	Trump Says Hell Set 50% Copper Tariff, Wait Year on Drug Levies (Bloomberg)
02:17PM	Uber's highs, Trump tariff warning, Wendys CEO heads to Hershey (Yahoo Finance Video)
10:43AM	AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth? (Zacks)
07:32AM	3 Disappointing Blue Chip Stocks That Have Crashed as Much as 87% in 10 Years (Motley Fool)
10:38AM	Loading…
Jul-07-25 10:38AM	Top 5 Undervalued Dividend Stocks With Strong Payout Potential (MarketBeat)
Jul-05-25 06:30AM	The Best Dividend Stocks I'd Buy Right Now (Motley Fool)
Jul-04-25 07:45AM	2 Stocks to Buy With Less Than $50 (Motley Fool)
06:28AM	HER2+ Breast Cancer Market Analysis and Forecasts Report 2025-2035 \| Emerging Markets and Players Shape Future of HER2-Positive Cancer Solutions (GlobeNewswire)
03:51AM	Prediction: 3 Magnificent Stocks That'll Be Worth More Than Palantir by 2028 (Motley Fool)
03:22AM	Pfizer Advances HYMPAVZI After Successful Hemophilia Trial Results (Insider Monkey)
Jul-03-25 08:30PM	Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons (Benzinga)
09:36AM	Robert F. Kennedy Jr. Just Did The Unexpected. He Helped Moderna. (Investor's Business Daily)
09:26AM	Will The Decline in Legacy Drugs Pull Down BMY's Top Line? (Zacks)
09:06AM	MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations (Zacks)
08:48AM	Pfizer Trades Above 50-Day Average for a Month: Time to Buy? (Zacks)
08:15AM	Activist investor Starboard Value discloses 9% stake in Tripadvisor (Reuters)
07:44AM	Regeneron nabs dosing edge with Lynozyfics FDA approval in multiple myeloma (Pharmaceutical Technology)
04:21AM	Is Pfizer Stock a Yield Trap? (Motley Fool)
03:51AM	3 Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 9% -- Which Make for No-Brainer Buys in July (Motley Fool)
Jul-02-25 05:45PM	Pfizer (PFE) Outperforms Broader Market: What You Need to Know (Zacks)
04:33PM	Kennedy Expands RSV Vaccine Recommendations. Moderna, Pfizer Shares Are Up. (Barrons.com)
01:30PM	Huge Unusual Volume in Pfizer Put Options Signals Investors Bullish Outlook (Barchart)
10:22AM	Analyst Report: Pfizer Inc. (Morningstar Research)
07:09AM	Pfizer terminates study of CD47 in blood cancer due to low recruitment (Clinical Trials Arena)
05:43AM	Semaglutide Market Forecast Report 2025-2033 \| Growth Accelerates Amid Rising Awareness, Regulatory Approvals, and Strong Pipeline Advancements (GlobeNewswire)
Jul-01-25 01:02PM	Improved Pharma initiates research and development program (PR Newswire)
11:06AM	Cannabis Lighting Market Report 2025-2030 \| Share Analysis, Industry Trends & Statistics, Growth Forecasts - Pfizer Ventures into Cannabis with $6.7 Billion Deal, Boosting Industry Growth (GlobeNewswire)
09:35AM	Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth (Zacks)
09:00AM	Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock (Zacks)
Jun-30-25 09:50AM	BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock? (Zacks)
Jun-29-25 09:28PM	XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations (PR Newswire)
Jun-28-25 06:35AM	3 No-Brainer Stocks to Buy for Under $100 Right Now (Motley Fool)
Jun-27-25 10:58AM	PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal (Zacks)
05:35AM	Pfizer reports positive results from Phase III BASIS trial for haemophilia (Clinical Trials Arena)
04:22AM	Sickle Cell Disease Treatment Market Analysis and Forecast, 2025-2035 \| Intensifying Competition as Key Players Advance Gene and Novel Therapies (GlobeNewswire)
Jun-26-25 12:00PM	All You Need to Know About Pfizer (PFE) Rating Upgrade to Buy (Zacks)
09:30AM	Smartlys Flagship Event ADVANCE Returns: New Voices, Big Ideas, and the Future of Marketing (Business Wire)
08:05AM	Innovation in Focus: Highlights from the Two-Day London Biotechnology Show 2025 (Pharmaceutical Technology)
06:45AM	Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI in Hemophilia A or B with Inhibitors (Business Wire)
Jun-25-25 05:30PM	Pfizer Declares Third-Quarter 2025 Dividend (Business Wire)
10:02AM	Will New Drugs Enable BMY to Offset the Impact of Generic Competition? (Zacks)
10:00AM	Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts (Business Wire)
08:00AM	Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors (GlobeNewswire)
06:15AM	Alzheimers R&D resurgence driven by $16.8bn in acquisitions in 2025YTD (Pharmaceutical Technology)
12:03AM	3 Reasons PFE is Risky and 1 Stock to Buy Instead (StockStory)
Jun-24-25 05:45PM	Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
10:25AM	Pfizer to Face Several Headwinds: Can It Successfully Navigate Them? (Zacks)
08:22AM	Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth? (Zacks)
07:10AM	My 5 Favorite Dirt Cheap Stocks to Buy Right Now (Motley Fool)
05:22AM	Kinase Inhibitors in Autoimmune Diseases Research Report 2025-2035 \| Market Accelerates Amid Rising Disease Prevalence, Kinase Innovation, and Demand for Safer Treatments (GlobeNewswire)
Jun-23-25 11:09PM	Pfizer's Dividend Backed by Strong Free Cash Flow (Insider Monkey)
12:48PM	Ireland Warns Thousands of Jobs at Risk From Pharma Tariffs (Bloomberg)
05:30AM	10 Stocks That Pay $100 or More in Dividends (Motley Fool)
12:09AM	The 5 Most Interesting Analyst Questions From Pfizer's Q1 Earnings Call (StockStory)
Jun-20-25 11:27AM	Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street. (Barrons.com)
10:01AM	Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now? (Zacks)
09:00AM	Is Trending Stock Pfizer Inc. (PFE) a Buy Now? (Zacks)
Jun-19-25 09:47AM	Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth? (Zacks)
03:00AM	Gene Therapy Has Lost Support on Wall Street. There's Still Hope for Big Cures. (Barrons.com)
Jun-18-25 10:00AM	Trump administration weighs crackdown on pharma ads, Bloomberg says (TipRanks)
07:00AM	2 Top Stocks to Buy With Less Than $30 (Motley Fool)
Jun-17-25 07:34PM	Analyst Report: Haleon plc (Morningstar Research)
05:16PM	Trump's big beautiful bill: What the pharma industry is watching (Yahoo Finance Video)
02:39PM	Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards? (Zacks)
11:20AM	Cantor Fitzgerald Maintains PFE At Neutral Amid Vaccine Guidance Changes and Regulatory Challenges (Insider Monkey)
11:18AM	AMD extends gains, solar stocks plummet, pharma stocks (Yahoo Finance Video)
10:32AM	Trump reportedly threatens pharma ads, disrupting $10B market (Yahoo Finance Video)
10:12AM	RFK Jr. Plans Crackdown on Pharma Ads in Threat to $10 Billion Market (Bloomberg)
09:40AM	Should Value Investors Buy Pfizer (PFE) Stock? (Zacks)
09:02AM	5 Low Price-to-Book Value Stocks That You Can Buy in June (Zacks)
04:49AM	Why I Just Bought More of This Beaten-Down 7%-Yielding Dividend Stock (Motley Fool)
Jun-16-25 11:40AM	PFE or LLY: Which Is the Better Value Stock Right Now? (Zacks)
11:20AM	EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy (Zacks)
09:29AM	4 Value Stocks to Shield Your Portfolio Amid Geopolitical Turmoil (Zacks)

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dolsten Mikael	Former Officer	May 23 '25	Proposed Sale	23.09	59,781	1,380,632		May 23 10:54 AM
Dolsten Mikael	Former Officer	May 05 '25	Proposed Sale	23.87	55,000	1,312,736		May 05 04:45 PM
DAMICO JENNIFER B.	SVP & Controller	Mar 04 '25	Sale	25.93	2,500	64,825	11,850	Mar 06 01:57 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 27 '25	Option Exercise	31.31	22,416	701,845	31,063	Mar 03 05:39 PM
SUSMAN SALLY	Executive Vice President	Feb 27 '25	Option Exercise	31.31	85,182	2,667,048	250,866	Mar 03 05:38 PM
SAHNI PAYAL	Executive Vice President	Feb 27 '25	Option Exercise	31.31	19,054	596,581	44,242	Mar 03 05:38 PM
McDermott Michael	Executive Vice President	Feb 27 '25	Option Exercise	31.31	48,419	1,515,999	122,413	Mar 03 05:37 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 27 '25	Option Exercise	31.31	156,914	4,912,977	309,790	Mar 03 05:37 PM
Fonseca Lidia	Executive Vice President	Feb 27 '25	Option Exercise	31.31	72,629	2,274,014	111,534	Mar 03 05:36 PM
BOURLA ALBERT	Chairman & CEO	Feb 27 '25	Option Exercise	31.31	582,823	18,248,188	931,744	Mar 03 05:36 PM
McDermott Michael	Executive Vice President	Feb 22 '25	Option Exercise	30.17	11,125	335,641	87,636	Feb 25 07:38 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 22 '25	Option Exercise	30.17	8,741	263,716	17,602	Feb 25 07:38 PM
BOURLA ALBERT	Chairman & CEO	Feb 22 '25	Option Exercise	30.17	238,399	7,192,498	570,436	Feb 25 07:06 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 22 '25	Option Exercise	30.17	85,824	2,589,310	232,775	Feb 25 07:05 PM
SAHNI PAYAL	Executive Vice President	Feb 22 '25	Option Exercise	30.17	12,714	383,581	37,099	Feb 25 07:04 PM
SUSMAN SALLY	Executive Vice President	Feb 22 '25	Option Exercise	30.17	63,573	1,917,997	225,184	Feb 25 07:02 PM
BOSHOFF CHRISTOFFEL	President, R&D	Feb 22 '25	Option Exercise	30.17	8,741	263,716	159,085	Feb 25 06:58 PM
BLAYLOCK RONALD E	Director	Feb 13 '25	Buy	25.65	19,457	499,072	27,707	Feb 14 05:16 PM
Gottlieb Scott	Director	Oct 30 '24	Buy	28.24	1,000	28,240	10,000	Oct 31 04:06 PM
DAMICO JENNIFER B.	SVP & Controller	Aug 13 '24	Sale	28.66	5,154	147,714	8,582	Aug 14 03:47 PM

TEM

Tempus AI Inc

PFE

Pfizer Inc

Upgrade your FINVIZ experience